{
    "id": 576,
    "fullName": "KDR act mut",
    "impact": "unknown",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "KDR act mut indicates that this variant results in a gain of function in the Kdr (Vegfr2) protein. However, the specific amino acid change has not been identified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "category",
    "gene": {
        "id": 3791,
        "geneSymbol": "KDR",
        "terms": [
            "KDR",
            "CD309",
            "FLK1",
            "VEGFR",
            "VEGFR2"
        ]
    },
    "variant": "act mut",
    "createDate": "05/14/2014",
    "updateDate": "09/13/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 1434,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Nexavar (sorafenib) demonstrated efficacy in cells expressing KDR activating mutations (PMID: 19723655).",
            "molecularProfile": {
                "id": 635,
                "profileName": "KDR act mut"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 217,
                    "pubMedId": 19723655,
                    "title": "KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19723655"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1023,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Lucitanib (E-3810) demonstrated safety and efficacy in patients with FGF-aberrant or angiogenesis-sensitive advanced solid tumors (PMID: 25193991).",
            "molecularProfile": {
                "id": 635,
                "profileName": "KDR act mut"
            },
            "therapy": {
                "id": 1029,
                "therapyName": "Lucitanib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 739,
                    "pubMedId": 25193991,
                    "title": "Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25193991"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1571,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing KDR activating mutations were sensitive to Sutent (sunitinib) in cell culture (PMID: 19723655).",
            "molecularProfile": {
                "id": 635,
                "profileName": "KDR act mut"
            },
            "therapy": {
                "id": 930,
                "therapyName": "Sunitinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 217,
                    "pubMedId": 19723655,
                    "title": "KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19723655"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 974,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial of patients with metastatic urothelial cancer, Sutent (sunitinib) demonstrated limited antitumor activity, warranting further investigation of VEGF pathways as a therapeutic target (PMID: 20142593).",
            "molecularProfile": {
                "id": 635,
                "profileName": "KDR act mut"
            },
            "therapy": {
                "id": 930,
                "therapyName": "Sunitinib",
                "synonyms": null
            },
            "indication": {
                "id": 4006,
                "name": "bladder urothelial carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 635,
                    "pubMedId": 20142593,
                    "title": "Phase II study of sunitinib in patients with metastatic urothelial cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20142593"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        }
    ],
    "molecularProfiles": [
        {
            "id": 635,
            "profileName": "KDR act mut",
            "profileTreatmentApproaches": [
                {
                    "id": 271,
                    "name": "VEGFR Inhibitor (Pan)",
                    "profileName": "KDR act mut"
                },
                {
                    "id": 272,
                    "name": "VEGFR2 Inhibitor",
                    "profileName": "KDR act mut"
                }
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}